Opus Genetics, Inc. Fair Value of Long-Term Debt
Opus Genetics, Inc. (IRD) had Fair Value of Long-Term Debt of $34.93 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt
us-gaap:LongTermDebtFairValue · last filed 2026-08-06
- 2026-06-30: Long-term Debt, Fair Value $34.93M.
- 2025-12-31: Long-term Debt, Fair Value $0.00.
| Period end | Long-term Debt, Fair Value |
|---|---|
| 2026-06-30 | $34.93M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |